Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BYC2
UPID:
SCOT2_HUMAN
Alternative names:
3-oxoacid CoA-transferase 2A; Testis-specific succinyl-CoA:3-oxoacid CoA-transferase
Alternative UPACC:
Q9BYC2; B2RBB4; Q5QPK4; Q8NHR1; Q9H1I4
Background:
Succinyl-CoA:3-ketoacid coenzyme A transferase 2, mitochondrial, also known as 3-oxoacid CoA-transferase 2A and Testis-specific succinyl-CoA:3-oxoacid CoA-transferase, plays a pivotal role in ketone body catabolism. It facilitates the transfer of the CoA moiety from succinate to acetoacetate, a critical step in the metabolic process. The enzyme operates through an intermediate anhydride species, highlighting a sophisticated mechanism of action.
Therapeutic significance:
Understanding the role of Succinyl-CoA:3-ketoacid coenzyme A transferase 2, mitochondrial could open doors to potential therapeutic strategies.